Innovative Cryoablation Technique Gains Ground in Breast Cancer Treatment
Groundbreaking Results in Breast Cancer Treatment
Professor Eisuke Fukuma, a prominent breast surgeon and expert in cryoablation, recently showcased significant data regarding IceCure's ProSense® at a leading conference focused on breast cancer. This independent study included over 600 women treated from 2006 to 2023, demonstrating remarkable outcomes for those facing this challenging diagnosis.
ProSense® Study Highlights
In an independent analysis led by Professor Hisanori Kawamoto, the research revealed an astonishing 0% local recurrence rate of breast cancer, earning the accolade of Best of Breast Cancer Award. This study highlights the effective nature of cryoablation as a viable treatment option.
Expert Insights on Cryoablation
Furthermore, renowned US breast surgeon Dr. Richard Fine presented findings from IceCure's ICE3 study alongside other notable publications. His insights validate the promising potential of cryoablation technology in enhancing cancer treatment outcomes.
Industry Collaboration for Better Outcomes
We believe that ProSense® can significantly contribute to better breast cancer outcomes by offering women a minimally invasive option. The engagement at this year's conference allowed for meaningful discussions among breast surgeons, industry leaders, and researchers,” said Eyal Shamir, CEO of IceCure.
Cryoablation Luncheon and Presentations
As a delighted sponsor of the conference, IceCure hosted a focused luncheon on cryoablation, led by Professor Takayuki Kinoshita from the NHO Tokyo Medical Center. The event featured a multitude of presentations from top experts on the latest advancements in cryoablation.
- Professor Eisuke Fukuma revealed prevailing data from his experience with over 600 breast cryoablation procedures mostly conducted using ProSense®. His findings indicated that from 2006 to 2023, there was an impressive 99.02% recurrence-free success rate over 17 years, making it a noteworthy option in breast cancer management.
- Dr. Richard Fine, associated with West Cancer Center & Research Institute, shared critical valuations from the ICE3 study alongside independent findings on the usage of ProSense® in breast cancer treatments.
Notably, the Best of Breast Cancer award was given for an independent study published in a prominent journal, tinged with findings that speak to the remarkable abilities of the ProSense® system in enabling lasting results.
Dr. Kawamoto expressed gratitude for the impactful outcomes of the study, where patients reported favorable clinical results alongside minimal hospital stays, aligning with the growing demand for effective yet less invasive treatment alternatives.
Anticipated Regulatory Approvals
Terumo Corporation is reportedly expected to initiate the regulatory process with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking clearance for ProSense® for breast cancer indications by the end of 2025.
About the ProSense® Technology
ProSense® refers to a cutting-edge cryoablation system that provides minimally invasive treatments to combat tumors through a freezing process. This system utilizes liquid nitrogen to form expansive lethal zones that ensure effective treatment of both benign and malignant tumors in breasts, kidneys, lungs, and liver.
The benefits are numerous, enhancing patient care by accelerating recovery times while reducing pain and associated surgical risks.
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) specializes in developing and marketing advanced liquid-nitrogen-based cryoablation systems that effectively destroy tumors by freezing. Focused primarily on breast, kidney, bone, and lung cancer, their pioneering technology serves as a safe, minimally invasive alternative to surgical tumor removal, making it accessible for outpatient care.
Frequently Asked Questions
What is the ProSense® system?
ProSense® is a cryoablation system that offers a minimally invasive solution for tumor destruction by utilizing freezing methods.
How effective is ProSense® in treating breast cancer?
Studies have shown it achieves a 99.02% recurrence-free rate, highlighting its effectiveness in breast cancer treatment.
Who presented at the Japanese Breast Cancer Society Conference?
Notable presenters included Professor Eisuke Fukuma and Dr. Richard Fine, sharing impactful data regarding cryoablation.
What are the benefits of using cryoablation?
Cryoablation enhances patient recovery, reduces pain, and minimizes surgical risks compared to traditional methods.
When is IceCure expecting regulatory approval for ProSense®?
Terumo Corporation aims to submit an application for approval to the PMDA in Japan by the end of 2025.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
